Cargando…
Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
BACKGROUND: Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients ≥15 years. Brexanolone is available commercially only through a restricted program (ZULRESSO(®) Risk Evaluation and Mitigation Strategy; REMS) due to risk of e...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491550/ https://www.ncbi.nlm.nih.gov/pubmed/37280463 http://dx.doi.org/10.1007/s40801-023-00372-4 |